Narendra Wajapeyee

4.9k total citations · 1 hit paper
95 papers, 3.7k citations indexed

About

Narendra Wajapeyee is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Narendra Wajapeyee has authored 95 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Molecular Biology, 27 papers in Oncology and 17 papers in Cancer Research. Recurrent topics in Narendra Wajapeyee's work include Epigenetics and DNA Methylation (26 papers), RNA modifications and cancer (17 papers) and Cancer-related gene regulation (11 papers). Narendra Wajapeyee is often cited by papers focused on Epigenetics and DNA Methylation (26 papers), RNA modifications and cancer (17 papers) and Cancer-related gene regulation (11 papers). Narendra Wajapeyee collaborates with scholars based in United States, Singapore and India. Narendra Wajapeyee's co-authors include Michael R. Green, Michael R. Green, Meera Mahalingam, Xiaochun Zhu, Arvindhan Nagarajan, Ryan W. Serra, Romi Gupta, Parmanand Malvi, Manas Kumar Santra and Suresh Bugide and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Narendra Wajapeyee

90 papers receiving 3.7k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7

2008 688 citations Narendra Wajapeyee, Meera Mahalingam et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Narendra Wajapeyee United States	31	2.7k	941	895	553	340	95	3.7k
Darjus F. Tschaharganeh Germany	22	2.3k 0.8×	583 0.6×	1.1k 1.2×	538 1.0×	397 1.2×	34	3.5k
Dimitris Athineos United Kingdom	26	2.6k 1.0×	996 1.1×	1.2k 1.4×	445 0.8×	192 0.6×	36	3.7k
Han You China	29	3.4k 1.3×	955 1.0×	1.1k 1.2×	476 0.9×	301 0.9×	41	4.5k
Gary G. Chiang United States	23	2.9k 1.1×	900 1.0×	666 0.7×	384 0.7×	240 0.7×	47	3.8k
Chengming Zhu United States	26	3.3k 1.2×	765 0.8×	1.3k 1.5×	981 1.8×	483 1.4×	62	4.4k
Francesca Bernassola Italy	37	3.0k 1.1×	647 0.7×	1.4k 1.6×	517 0.9×	286 0.8×	71	4.2k
John Easton United States	32	2.3k 0.9×	678 0.7×	675 0.8×	413 0.7×	143 0.4×	84	3.5k
Andrea Morrione United States	40	3.2k 1.2×	866 0.9×	924 1.0×	307 0.6×	262 0.8×	92	4.7k
John G. Clohessy United States	28	2.9k 1.1×	1.4k 1.5×	756 0.8×	411 0.7×	368 1.1×	50	3.7k
Kian‐Huat Lim United States	29	2.4k 0.9×	752 0.8×	1.6k 1.8×	781 1.4×	238 0.7×	97	4.2k

Countries citing papers authored by Narendra Wajapeyee

Since Specialization

Citations

This map shows the geographic impact of Narendra Wajapeyee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narendra Wajapeyee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narendra Wajapeyee more than expected).

Fields of papers citing papers by Narendra Wajapeyee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Narendra Wajapeyee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narendra Wajapeyee. The network helps show where Narendra Wajapeyee may publish in the future.

Co-authorship network of co-authors of Narendra Wajapeyee

This figure shows the co-authorship network connecting the top 25 collaborators of Narendra Wajapeyee. A scholar is included among the top collaborators of Narendra Wajapeyee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Narendra Wajapeyee. Narendra Wajapeyee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gupta, Romi, Raj Kumar, Courtney A. Penn, & Narendra Wajapeyee. (2025). Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments. Trends in Immunology. 46(2). 166–181. 6 indexed citations

Wajapeyee, Narendra, et al.. (2025). NSD proteins in anti-tumor immunity and their therapeutic targeting by protein degraders. Cellular and Molecular Life Sciences. 82(1). 268–268. 2 indexed citations

Malvi, Parmanand, Suresh Bugide, Yvonne J. K. Edwards, et al.. (2025). PDE7A inhibition suppresses triple-negative breast cancer by attenuating de novo pyrimidine biosynthesis. Cell Reports Medicine. 6(9). 102356–102356.

Malvi, Parmanand, Guoping Cai, Kai Hu, et al.. (2023). HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B. Cell Reports Medicine. 4(11). 101285–101285. 9 indexed citations

Bugide, Suresh, Yvonne J. K. Edwards, Romi Gupta, Michael R. Green, & Narendra Wajapeyee. (2023). CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. Proceedings of the National Academy of Sciences. 120(4). e2218118120–e2218118120. 10 indexed citations

Akce, Mehmet, Bassel F. El‐Rayes, & Narendra Wajapeyee. (2023). Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy. Oncogene. 42(14). 1051–1057. 13 indexed citations

Malvi, Parmanand, et al.. (2023). LIMK2 promotes melanoma tumor growth and metastasis through G3BP1-ESM1 pathway-mediated apoptosis inhibition. Oncogene. 42(18). 1478–1491. 7 indexed citations

Bugide, Suresh, Romi Gupta, Michael R. Green, & Narendra Wajapeyee. (2021). EZH2 inhibits NK cell–mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. Proceedings of the National Academy of Sciences. 118(30). 56 indexed citations

Pan, Lili, Chao Hong, Lai N. Chan, et al.. (2021). PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. Proceedings of the National Academy of Sciences. 118(7). 13 indexed citations

10.

Malvi, Parmanand, Deborah Della Manna, Eddy S. Yang, et al.. (2021). PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1. Oncogene. 40(13). 2448–2462. 30 indexed citations

11.

Gupta, Romi, Radoslav Janoštiak, & Narendra Wajapeyee. (2020). Transcriptional regulators and alterations that drive melanoma initiation and progression. Oncogene. 39(48). 7093–7105. 23 indexed citations

12.

Malvi, Parmanand, Radoslav Janoštiak, Esther Yoon, et al.. (2020). LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1. Oncogenesis. 9(8). 77–77. 34 indexed citations

13.

Malvi, Parmanand, Radoslav Janoštiak, Arvindhan Nagarajan, Guoping Cai, & Narendra Wajapeyee. (2019). Loss of thymidine kinase 1 inhibits lung cancer growth and metastatic attributes by reducing GDF15 expression. PLoS Genetics. 15(10). e1008439–e1008439. 34 indexed citations

14.

Bisserier, Malik & Narendra Wajapeyee. (2018). Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas. Blood. 131(19). 2125–2137. 98 indexed citations

15.

Gupta, Romi, Matteo Forloni, Malik Bisserier, et al.. (2016). Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growth. eLife. 5. 21 indexed citations

16.

Forloni, Matteo, Romi Gupta, Arvindhan Nagarajan, et al.. (2016). Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells. Cell Reports. 16(2). 457–471. 55 indexed citations

17.

Lin, Ling, Lynn Chamberlain, Arvindhan Nagarajan, et al.. (2014). A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling. Cancer Discovery. 4(10). 1168–1181. 15 indexed citations

18.

Yang, Shi, et al.. (2010). Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7—challenging the concept of dysplastic nevi as precursor lesions?. Human Pathology. 41(6). 886–894. 22 indexed citations

19.

Wajapeyee, Narendra, Varun Kapoor, Meera Mahalingam, & Michael R. Green. (2009). Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Molecular Cancer Therapeutics. 8(11). 3009–3014. 39 indexed citations

20.

Wajapeyee, Narendra, Manas Kumar Santra, Claude Gazin, et al.. (2009). Epigenetic Silencing of the RASSF1A Tumor Suppressor Gene through HOXB3-Mediated Induction of DNMT3B Expression. Molecular Cell. 36(2). 219–230. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact